Glaucoma Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Glaucoma - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye's optic nerve, resulting in progressive, irreversible vision loss.

Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. Glaucoma is divided into POAG, PACG, or SG. POAG is further divided into high tension glaucoma (HTG) if intraocular pressure (IOP) is greater than 21mm HG, and NTG if IOP is less than 21mm HG. POAG in this report represents OAG with HTG.

PPG, also known as glaucoma suspect, is also included in the glaucoma types. Although there are many types of glaucoma, the two most important types are POAG and PACG, with POAG accounting for approximately 80-90% of all glaucoma cases.

To forecast the total and diagnosed prevalent cases in 7MM, the publisher epidemiologists obtained nationally representative, population-based studies that provided these epidemiological data in the 7MM. The publisher epidemiologists used age- and sex-specific total and diagnosed prevalence rates to forecast the total and diagnosed prevalent cases, considering the significant relationship between age and glaucoma.

The following data describes epidemiology of POAG and PACG cases. In 2020, the 7MM had 7,289,907 total prevalent cases of POAG. This is expected to increase to 8,835,233 total prevalent cases by 2030, at an Annual Growth Rate (AGR) of 2.12%. In the 7MM, the total prevalent cases of PACG will increase from 1,781,968 cases in 2020 to 2,065,644 cases in 2030, at an AGR of 1.59%.

This increase is partly attributed to the moderately rising trend in prevalence in the 7MM, combined with underlying demographic changes in the respective markets. The early diagnosis and development of more effective therapies would improve the outcome for glaucoma patients.

Scope

• Glaucoma Epidemiology Report provides an overview of the risk factors and global trends of glaucoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• This report also includes a 10-year epidemiological forecast for the following segmentations in ?40 years the 7MM: total prevalent cases and diagnosed prevalent cases of primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG), segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and ages 80 years and older). In addition, this report also provides a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of following glaucoma clinical types: normal-tension glaucoma (NTG), pre perimetric glaucoma (PPG), and secondary glaucoma (SG). The report also includes the diagnosed incident cases of acute PACG and diagnosed prevalent cases of acute and chronic PACG.
• The Glaucoma Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Key Topics Covered:

1 Glaucoma: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Total Prevalent Cases of POAG

2.4.4 Total Prevalent Cases of PACG

2.4.5 Total Prevalent Cases of NTG and PPG

2.4.6 Total Prevalent Cases of SG

2.4.7 Diagnosed Prevalent Cases

2.4.8 Diagnosed Incident Cases of Acute PACG

2.5 Epidemiological Forecast for Glaucoma (2020 - 2030)

2.5.1 Total Prevalent Cases of POAG

2.5.2 Age-Specific Total Prevalent Cases of POAG

2.5.3 Sex-Specific Total Prevalent Cases of POAG

2.5.4 Total prevalent Cases of PACG

2.5.5 Age-Specific Total Prevalent Cases of PACG

2.5.6 Sex-Specific Total Prevalent Cases of PACG

2.5.7 Total Prevalent Cases of NTG

2.5.8 Total Prevalent Cases of SG

2.5.9 Total Prevalent Cases of PPG

2.5.10 Diagnosed Prevalent Cases of POAG

2.5.11 Diagnosed Prevalent Cases of PACG

2.5.12 Diagnosed Prevalent Cases of Acute and Chronic PACG

2.5.13 Diagnosed Incident Cases of Acute PACG

2.5.14 Diagnosed Prevalent Cases of NTG

2.5.15 Diagnosed Prevalent Cases of SG

2.5.16 Diagnosed Prevalent Cases of PPG

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/fkf286